III. Remarks

A. Status of the Application

Claims 1-31 are pending herein.

B. Restriction Requirement

The Office action mailed December 16, 2004 requires restriction under 35 U.S.C. §121 to one of the following groups of claims:

- Group I Claim 1, drawn to a method for the treatment of alcohol dependence comprising the oral administration of a dietary supplement comprising acetylated mannose, gum ghatti, gum tragacanth, glucosamine, corn starch and arabinogalactan, wherein at least a portion of the ingredients are predigested.
- Group II Claim 2, drawn to a method for the reduction of undesired side effects in humans receiving an agent that causes side effects comprising the oral administration of a dietary supplement comprising acetylated mannose, gum ghatti, gum tragacanth, glucosamine, corn starch and arabinogalactan, wherein at least a portion of the ingredients are predigested.
- Group III Claims 3-8, drawn to a method for producing correctly structured and properly functioning glycoproteins and/or glycolipids comprising administering a nutritionally effective amount of at least one saccharide selected from a group of sixteen saccharides.
- Group IV Claims 9-10, drawn to a method for producing correctly structured and properly functioning glycoproteins and/or glycolipids comprising administering a composition comprising 10 weight percent acetylated mannose, 10 weight percent gum tragacanth, 10 weight percent glucosamine, 12 weight percent corn starch and 48 weight percent arabinogalactan.
- Group V Claim 11, drawn to a method of providing a host in need of essential saccharides with a dietary supplement composition comprising acetylated mannose, a first saccharide selected from a group of 5 saccharides and a second saccharide selected from a group of 9 saccharides.
- Group VI Claim 12, drawn to a method of providing a subject with essential saccharides comprising administering at least two saccharides wherein one of the saccharides is selected from a group of 4 saccharides and the other of the saccharides is selected from a group of 12 saccharides.
- Group VII Claims 13-17, drawn to a method for the promotion and maintenance of good health comprising the administration of at least two monosaccharides selected

from a group of 13 saccharides.

- Group VIII Claim 18, drawn to a method for the treatment of alcohol dependence comprising the oral administration of a dietary supplement comprising acetylated mannose, gum ghatti, gum tragacanth, glucosamine, corn starch and arabinogalactan.
- Group IX Claim 19, drawn to a method for the reduction of undesired side effects in humans receiving an agent that causes side effects comprising the oral administration of a dietary supplement comprising acetylated mannose, gum ghatti, gum tragacanth, glucosamine, corn starch and arabinogalactan.
- Group X Claims 20-25, drawn to a method for producing correctly structured and properly functioning glycoproteins and/or glycoproteins comprising administering a dietary supplement comprising six saccharides, selected from a group of 16 saccharides.
- Group XI Claims 26-27, drawn to a method for producing correctly structured and properly functioning glycoproteins and/or glycoproteins comprising administering a composition comprising 10 weight percent acetylated mannose, 10 weight percent gum tragacanth, 10 weight percent glucosamine, 12 weight percent corn starch and 48 weight percent arabinogalactan.
- Group XII Claims 28-31, drawn to a method for treating or preventing reduced glyconutrient levels of at least one saccharide by periodically administering a single formulation having 1-25 weight percent of arabinogalactan, glucosamine, rhamnose and acetylated mannose.

Applicants hereby elect with traverse, for prosecution herein, the claims of Group III, i.e. claims 3-8. If the Examiner maintains as final the restriction requirement between the claims of Groups I-XII as noted above, Applicants will take the position that the Examiner has admitted one group of claims to be patentable over the other, and that any prior art must be closer to the elected group of claims than the non-elected group of claims to render the elected group of claims unpatentable.

C. Conclusion

It is believed that all matters set forth in the Office action have been addressed. Favorable consideration and an early indication of the allowability of the elected claims are respectfully requested. Should the Examiner deem that an interview with Applicants'

undersigned attorney would expedite consideration of the elected claims, the Examiner is invited to call the undersigned attorney at the telephone number indicated below.

Respectfully submitted

Randall C. Brown Reg. No. 31,213

Dated: 11805

HAYNES AND BOONE, LLP 901 Main Street, Suite 3100 Dallas, Texas 75202-3789 Telephone: 214.651.5242

Facsimile: 214.200.0853

File: 23100.64